Journal article
hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
Cancers, Vol.14(4), 863
02/01/2022
DOI: 10.3390/cancers14040863
PMCID: PMC8870162
PMID: 35205614
Abstract
Simple Summary Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG(80)) can be easily measured in plasma by ELISA. This study is the first to examine hPG(80) in NENs. The study demonstrated increased levels of hPG(80) in all sub-types of NENs, with a high sensitivity and specificity demonstrated. Plasma hPG(80) in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG(80) as a means of monitoring disease (NCT04750954). Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG(80)) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG(80) in NENs. Plasma hPG(80) was quantified from 95 stage IV NEN patients, using DxPG(80) technology (ECS Progastrin, Switzerland) and compared with hPG(80) concentrations in two cohorts of healthy donor controls aged 50-80 (n = 252) and 18-25 (n = 137). Median hPG(80) in NENs patients was 5.54 pM compared to 1.5 pM for the 50-80 controls and 0.29 pM the 18-25 cohort (p < 0.0001). Subgroup analysis revealed median hPG(80) levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; n = 25) and neuroendocrine tumors (NET; n = 70) including the small-cell lung cancer (SCLC) sub-cohort (n = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG(80) in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG(80) as a means of monitoring disease (NCT04750954).
Details
- Title: Subtitle
- hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
- Creators
- Aman Chauhan - Markey Cancer CenterAlexandre Prieur - ECS Progastrin, CH-1004 Lausanne, SwitzerlandJill Kolesar - University of KentuckySusanne Arnold - University of KentuckyLea Payen - Hôpital Lyon SudYounes Mahi - ECS Progastrin, CH-1004 Lausanne, SwitzerlandBerengere Vire - ECS Progastrin, CH-1004 Lausanne, SwitzerlandMadison Sands - University of KentuckyB. Mark Evers - University of KentuckyDominique Joubert - ECS Progastrin, CH-1004 Lausanne, SwitzerlandLowell Anthony - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- Cancers, Vol.14(4), 863
- Publisher
- Mdpi
- DOI
- 10.3390/cancers14040863
- PMID
- 35205614
- PMCID
- PMC8870162
- eISSN
- 2072-6694
- Number of pages
- 8
- Language
- English
- Date published
- 02/01/2022
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695790702771
Metrics
1 Record Views